Document Type : Review Article
Authors
1 Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
2 Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Bangkok, 10700, Thailand.
3 E.N.T. Department, Worcester Royal Hospital, Worcester, UK
Abstract
Platelets are tiny (2-4 m), anucleate, hematopoietic cells that are discharged into the circulation by bone marrow megakaryocytes. Platelets were formerly thought to be the main agents of hemostasis and thrombosis. Armand Trousseau established a strong link between thrombosis and cancer in 1865. The hypothesis that platelets play many roles in the development of malignancies and in cancer-associated thrombosis is thus supported by a wealth of clinical and experimental data.The functions of tumor-educated platelets (TEPs) in the development of cancer, from primary tumors to subsequent metastatic breakouts, will be covered in this study
Keywords
1.S. Karpatkin, E. Pearlstein, C. Ambrogio, B.S. Coller, Role
of adhesive proteins in platelet tumor interaction in vitro
and metastasis formation in vivo, J. Clin. Invest.81. 1988
; 1012–1019,
2.O. Engebraaten, M. Trikha, S. Juell, S. Garman-Vik,
Ø. Fodstad, Inhibition of in vivo tumour growth by
the blocking of host alpha(v)beta3 and alphaII(b)beta3
integrins, Anticancer Res. 29. 2009; 131–137.
3.M.R. Weber, M. Zuka, M. Lorger, M. Tschan, B.E. Torbett, A.
Zijlstra, J.P. Quigley,K. Staflin, B.P. Eliceiri, J.S. Krueger,
P. Marchese, Z.M. Ruggeri, B.H. Felding,Activated tumor
cell integrin αvβ3 cooperates with platelets to promote
extravasation and metastasis from the blood stream,
Thromb. Res. 140 (Suppl.)2016 ; S27–36.
4.B. Felding-Habermann, T.E. O’Toole, J.W. Smith, E.
Fransvea, Z.M. Ruggeri,M.H. Ginsberg, P.E. Hughes, N.
Pampori, S.J. Shattil, A. Saven, B.M. Mueller,Integrin
activation controls metastasis in human breast cancer,
Proc. Natl. Acad.Sci. U. S. A. 98 .2001;1853–1858.
5.S. Mezouar, R. Darbousset, F. Dignat-George, L. Panicot-
Dubois, C. Dubois,Inhibition of platelet activation prevents
the P-selectin and integrin-dependent accumulation of
cancer cell microparticles and reduces tumor growth and
metastasis in vivo, Int. J. Cancer 136. 2015; 462–475.
6.S. Gebremeskel, T. LeVatte, R.S. Liwski, B. Johnston, M.
Bezuhly, The reversible P2Y12 inhibitor ticagrelor inhibits
metastasis and improves survival in mouse models of
cancer, Int. J. Cancer 136 .2015; 234–240.
7.N. Fujita, S. Takagi, The impact of Aggrus/podoplanin on
platelet aggregation and tumour metastasis, J. Biochem.
(Tokyo) 152. 2012 407–413.
8.Y. Kato, M. Kaneko, M. Sata, N. Fujita, T. Tsuruo, M.
Osawa, Enhanced expression of Aggrus (T1alpha/
Podoplanin), a platelet-aggregation-inducing factor in lung
squamous cell carcinoma, Tumor Biol. 26 .2005 ; 195–200.
9.S. Takagi, T. Oh-hara, S. Sato, B. Gong, M. Takami, N.
Fujita, Expression of Aggrus/podoplanin in bladder
cancer and its role in pulmonary metastasis, Int. J.Cancer
134.2014; 2605–2614.
10.Y. Kato, N. Fujita, A. Kunita, S. Sato, M. Kaneko, M.
Osawa, T. Tsuruo, Molecular identification of Aggrus/
T1alpha as a platelet aggregation-inducing factor
expressed in colorectal tumors, J. Biol. Chem. 278. 2003;
51599–51605.
11.C.L. Chaffer, R.A. Weinberg, A perspective on cancer cell
metastasis, Science 331.2011; 1559–1564
12.H. Läubli, L. Borsig, Selectins as mediators of lung
metastasis, Cancer Microenviron. 3 .2010 ; 97–105.
13.Y. Liu, P. Jiang, K. Capkova, D. Xue, L. Ye, S.C. Sinha,
N. Mackman, K.D. Janda, C. Liu, Tissue factor-activated
coagulation cascade in the tumor microenvironment is
critical for tumor progression and an effective target for
therapy, Cancer Res. 71. 2011 ; 6492–6502,
14.W. Ruf, N. Yokota, F. Schaffner, Tissue factor in cancer
progression and angio- genesis, Thromb. Res. 125 .2010;
S36–S38.
15.H.-M. Ko, H.H. Jung, K.H. Seo, Y.-R. Kang, H.-A. Kim,
S.J. Park, H.-K. Lee, S.-Y. Im, Platelet-activating factor-
induced NF-kappaB activation enhances VEGF expres-
sion through a decrease in p53 activity, FEBS Lett. 580
(2006) 3006–3012.
16.L. Sun, Z. He, J. Ke, S. Li, X. Wu, L. Lian, X. He, X.
He, J. Hu, Y. Zou, X. Wu, P. Lan, PAF receptor antagonist
Ginkgolide B inhibits tumourigenesis and angiogenesis
in colitis-associated cancer, Int. J. Clin. Exp. Pathol. 8
.2015; 432–440.
17. B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-
Pleszczynski,G. Montrucchio, G. Camussi, PAF produced
by human breast cancer cells promotes migration and
proliferation of tumor cells and neo-angiogenesis, Am. J.
Pathol.157 .2000; 1713–1725.
18.M. Labelle, S. Begum, R.O. Hynes, Direct signaling
between platelets and cancer cells induces an epithelial-
mesenchymal-like transition and promotes metastasis,
Cancer Cell 20 .2011; 576–590.
19.Y. Wang, H. Zhang, Platelet-induced inhibition of tumor
cell growth, Thromb. Res. 123 .2008; 324–330.
20.J.V. Michael, J.G.T. Wurtzel, G.F. Mao, A.K. Rao, M.A.
Kolpakov, A. Sabri,N.E. Hoffman, S. Rajan, D. Tomar, M.
Madesh, M.T. Nieman, J. Yu, L.C. Edelstein, J.W. Rowley,
A.S. Weyrich, L.E. Goldfinger, Platelet microparticles
infiltrating solid tumors transfer miRNAs that suppress
tumor growth, Blood 130 .2017; 567–580.
21. J.F. Di Stefano, M. Kirchner, K. Dagenhardt, N. Hagag,
Activation of cancer cell proteases and cytotoxicity by
EGF and PDGF growth factors, Am J Med Sci 300 .1990;
9–15.
22.J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer:
biological implications and therapeutic opportunities, Nat.
Rev. Cancer 10 .2010; 9–22.
23.T.E. Maione, G.S. Gray, J. Petro, A.J. Hunt, A.L.
Donner, S.I. Bauer, H.F. Carson, R.J. Sharpe, Inhibition of
angiogenesis by recombinant human platelet factor-4 and
related peptides, Science 247 .1990; 77–79.
24.S. Struyf, M.D. Burdick, P. Proost, J.V. Damme, R.M.
Strieter, Platelets release CXCL4L1, a nonallelic variant
of the chemokine platelet Factor-4/CXCL4 and potent
inhibitor of angiogenesis, Circ. Res. 95 .2004; 855–857.
25.S. Struyf, M.D. Burdick, E. Peeters, K.V. den Broeck,
C. Dillen, P. Proost,J.V. Damme, R.M. Strieter, Platelet
Factor-4 variant chemokine CXCL4L1 inhibits melanoma
and lung carcinoma growth and metastasis by preventing
angiogenesis, Cancer Res. 67.2007; 5940–5948.
26.J. Vandercappellen, S. Liekens, A. Bronckaers, S. Noppen,
I. Ronsse, C. Dillen, M. Belleri, S. Mitola, P. Proost, M.
Presta, S. Struyf, J. Van Damme, The COOH- terminal
peptide of platelet factor-4 variant (CXCL4L1/PF-
4var47-70) strongly inhibits angiogenesis and suppresses
B16 melanoma growth in vivo, Mol. Cancer Res. 8(2010) 322–334.
27.P. Allavena, A. Sica, C. Garlanda, A. Mantovani, The
yin-Yang of tumor-associated macrophages in neoplastic
progression and immune surveillance, Immunol. Rev.
222 (2008) 155–161.
28.G.T. Lee, J.H. Hong, C. Kwak, J. Woo, V. Liu, C.
Lee, I.Y. Kim, Effect of dominant negative transforming
growth factor-beta receptor type II on cytotoxic activity of
RAW 264.7, a murine macrophage cell line, Cancer Res.
67 (2007) 6717–6724.
29.L. Shen, J.M. Smith, Z. Shen, M. Eriksson, C.
Sentman, C.R. Wira, Inhibition of human neutrophil
degranulation by transforming growth factor-β1, Clin.
Exp. Immunol. 149 (2007) 155–161.
30.M. Labelle, S. Begum, R.O. Hynes, Platelets guide the
formation of early metastatic niches, Proc. Natl. Acad.
Sci. U. S. A. 111 (2014) E3053–3061.
31.S. Mezouar, D. Mege, R. Darbousset, D. Farge, P.
Debourdeau, F. Dignat-George, L. Panicot-Dubois, C.
Dubois, Involvement of platelet-derived microparticles
in tumor progression and thrombosis, Semin. Oncol.
41 (2014) 346–358.
32.C. Yang, R. Ma, T. Jiang, M. Cao, L. Zhao, Y. Bi, J.
Kou, J. Shi, X. Zou, Contributions of phosphatidylserine-
positive platelets and leukocytes and micro- particles to
hypercoagulable state in gastric cancer patients, Tumor
Biol. 37 (2016) 7881–7891.
33.A. Rank, S. Liebhardt, J. Zwirner, A. Burges, R.
Nieuwland, B. Toth, Circulating microparticles in patients
with benign and malignant ovarian tumors, Anticancer
Res. 32 (2012) 2009–2014.
34.J.G. Ren, Q.W. Man, W. Zhang, C. Li, X.P. Xiong, J.Y.
Zhu, W.M. Wang, Z.J. Sun, J. Jia, W.F. Zhang, Y.F. Zhao, G.
Chen, B. Liu, Elevated level of circulating platelet- derived
microparticles in oral cancer, J. Dent. Res. 95 (2016) 87–
93.
35.C.-C. Tseng, C.-C. Wang, H.-C. Chang, T.-H. Tsai, L.-T.
Chang, K.-T. Huang, S. Leu, C.-H. Yen, S.-F. Liu, C.-H.
Chen, C.-T. Yang, H.-K. Yip, M.-C. Lin, Levels of circu-
lating microparticles in lung cancer patients and possible
prognostic value, Dis. Markers 35 (2013) 301–310.
36.L. Zhao, Y. Bi, J. Kou, J. Shi, D. Piao, Phosphatidylserine
exposing-platelets and microparticles promote
procoagulant activity in colon cancer patients, J. Exp. Clin.
Cancer Res. 35 (2016).
37.B. Toth, S. Liebhardt, K. Steinig, N. Ditsch, A. Rank,
I. Bauerfeind, M. Spannagl, K. Friese, A.J. Reininger,
Platelet-derived microparticles and coagulation activa-
tion in breast cancer patients, Thromb. Haemost. 100
(2008) 663–669.
38.K. Haubold, M. Rink, B. Spath, M. Friedrich, F.K.-H.
Chun, G. Marx, A. Amirkhosravi, J.L. Francis, C.
Bokemeyer, B. Eifrig, F. Langer, Tissue factor procoagulant
activity of plasma microparticles is increased in patients
with early- stage prostate cancer, Thromb. Haemost. 101
(2009) 1147–1155.
39.F. van Doormaal, A. Kleinjan, R.J. Berckmans, N.
Mackman, D. Manly,P.W. Kamphuisen, D.J. Richel, H.R.
Büller, A. Sturk, R. Nieuwland, Coagulation activation
and microparticle-associated coagulant activity in cancer
patients, Thromb. Haemost. 108 (2012) 160–165..
40.E. Campello, L. Spiezia, C.M. Radu, C. Bulato, M.
Castelli, S. Gavasso, P. Simioni, Endothelial, platelet,
and tissue factor-bearing microparticles in cancer patients
with and without venous thromboembolism, Thromb.
Res. 127 (2011) 473–477.
41.O.P. Barry, D. Pratico, J.A. Lawson, G.A. FitzGerald,
Transcellular activation of platelets and endothelial cells
by bioactive lipids in platelet microparticles, J. Clin.
Invest. 99 (1997) 2118–2127.
42.S. Miyamoto, M.A. Kowalska, C. Marcinkiewicz,
M.M. Marcinkiewicz, D. Mosser, L.H. Edmunds, S.
Niewiarowski, Interaction of leukocytes with platelet
micro- particles derived from outdated platelet
concentrates, Thromb. Haemost. 80 (1998) 982–988.
43.M. Baj-Krzyworzeka, M. Majka, D. Pratico, J. Ratajczak,
G. Vilaire, J. Kijowski, R. Reca, A. Janowska-Wieczorek,
M.Z. Ratajczak, Platelet-derived microparticles stimulate
proliferation, survival, adhesion, and chemotaxis of
hematopoietic cells, Exp. Hematol. 30 (2002) 450–459.
44.H.K. Kim, K.S. Song, J.-H. Chung, K.R. Lee, S.-N. Lee,
Platelet microparticles in- duce angiogenesis in vitro, Br. J.
Haematol. 124 (2004) 376–384.
45.A. Janowska-Wieczorek, M. Wysoczynski, J. Kijowski,
L. Marquez-Curtis,B. Machalinski, J. Ratajczak, M.Z.
Ratajczak, Microvesicles derived from activated platelets
induce metastasis and angiogenesis in lung cancer, Int.
J. Cancer 113 (2005) 752–760.
46.A. Janowska-Wieczorek, L.A. Marquez-Curtis, M.
Wysoczynski, M.Z. Ratajczak,Enhancing effect of platelet-
derived microvesicles on the invasive potential of breast
cancer cells, Transfusion (Paris) 46 (2006) 1199–1209.
47.O. Dashevsky, D. Varon, A. Brill, Platelet-derived
microparticles promote inva- siveness of prostate cancer
cells via upregulation of MMP-2 production, Int. J.
Cancer 124 (2009) 1773–1777.
48.H. Liang, X. Yan, Y. Pan, Y. Wang, N. Wang, L. Li, Y.Liu, X. Chen, C.-Y. Zhang, H. Gu, K. Zen, MicroRNA-223
delivered by platelet-derived microvesicles pro- motes
lung cancer cell invasion via targeting tumor suppressor
EPB41L3, Mol. Cancer 14 .2015; 58.
49.A. Laios, S. O’Toole, R. Flavin, C. Martin, L. Kelly,
M. Ring, S.P. Finn, C. Barrett, M. Loda, N. Gleeson, T.
D’Arcy, E. McGuinness, O. Sheils, B. Sheppard, J.O’.
Leary, Potential role of miR-9 and miR-223 in recurrent
ovarian cancer, Mol. Cancer 7 .2008 ; 35.
50. D.L. Sprague, B.D. Elzey, S.A. Crist, T.J. Waldschmidt,
R.J. Jensen, T.L. Ratliff, Platelet-mediated modulation
of adaptive immunity: unique delivery of CD154 signal
by platelet-derived membrane vesicles, Blood 111 .2008;
5028–5036.
51. Y. Liu, P. Jiang, K. Capkova, D. Xue, L. Ye, S.C. Sinha,
N. Mackman, K.D. Janda,C. Liu, Tissue factor-activated
coagulation cascade in the tumor microenvironment is
critical for tumor progression and an effective target for ;
52.W. Ruf, N. Yokota, F. Schaffner, Tissue factor in cancer
progression and angiogenesis,Thromb. Res. 125 .2010;
S36–S38.
53.H.-M. Ko, H.H. Jung, K.H. Seo, Y.-R. Kang, H.-A.
Kim, S.J. Park, H.-K. Lee, S.-Y. Im,Platelet-activating
factor-induced NF-kappaB activation enhances VEGF
expressionthrough a decrease in p53 activity, FEBS Lett.
580 .2006 ; 3006–3012.
54.L. Sun, Z. He, J. Ke, S. Li, X. Wu, L. Lian, X. He, X.
He, J. Hu, Y. Zou, X. Wu, P. Lan,PAF receptor antagonist
Ginkgolide B inhibits tumourigenesis and angiogenesis in
colitis-associated cancer, Int. J. Clin. Exp. Pathol. 8.2015;
432–440.
55. B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-
Pleszczynski,G. Montrucchio, G. Camussi, PAF produced
by human breast cancer cells promotes migration and
proliferation of tumor cells and neo-angiogenesis, Am. J.
Pathol. 157 .2000 ; 1713–1725.
56.F. Bussolino, M. Arese, G. Montrucchio, L. Barra, L.
Primo, R. Benelli, F. Sanavio,M. Aglietta, D. Ghigo, M.R.
Rola-Pleszczynski, Platelet activating factor produced in
vitro by Kaposi’s sarcoma cells induces and sustains in
vivo angiogenesis, J.Clin. Invest. 96 .1995 ; 940–952.
57.E.G. Robert, J.D. Hunt, Lipid messengers as targets for
antiangiogenic therapy,Curr. Pharm. Des. 7 .2001 ; 1615–
1626.
58.J.S. Palumbo, K.E. Talmage, J.V. Massari, C.M.L.
Jeunesse, M.J. Flick,K.W. Kombrinck, M. Jirousková,
J.L. Degen, Platelets and fibrin(ogen) increase metastatic
potential by impeding natural killer cell-mediated
elimination of tumor cells, Blood 105 .2005; 178–185.
59.H.-G. Kopp, T. Placke, H.R. Salih, Platelet-derived
transforming growth factor-beta down-regulates
NKG2D thereby inhibiting natural killer cell antitumor
reactivity,Cancer Res. 69.2009; 7775–7783.
60.K. Egan, N. Cooke, D. Kenny, Living in shear: platelets
protect cancer cells from shear induced damage, Clin. Exp.
Metastasis 31 .2014; 697–704.
61.S. Karpatkin, E. Pearlstein, C. Ambrogio, B.S. Coller,
Role of adhesive proteins in platelet tumor interaction in
vitro and metastasis formation in vivo, J. Clin. Invest. 81
1988; 1012–1019.
62.O. Engebraaten, M. Trikha, S. Juell, S. Garman-Vik,.
Fodstad, Inhibition of in vivo tumour growth by the
blocking of host alpha(v)beta3 and alphaII(b)beta3
integrins, Anticancer Res. 29. 2009; 131–137.
63.M.R. Weber, M. Zuka, M. Lorger, M. Tschan, B.E.
Torbett, A. Zijlstra, J.P. Quigley,K. Staflin, B.P.
Eliceiri, J.S. Krueger, P. Marchese, Z.M. Ruggeri, B.H.
Felding,Activated tumor cell integrin αv β3 cooperates
with platelets to promote extravasation and metastasis
from the blood stream, Thromb. Res. 140 (Suppl. 1) .2016
; S27–36.
64.B. Felding-Habermann, T.E. O’Toole, J.W. Smith, E.
Fransvea, Z.M. Ruggeri,M.H. Ginsberg, P.E. Hughes, N.
Pampori, S.J. Shattil, A. Saven, B.M. Mueller,Integrin
activation controls metastasis in human breast cancer,
Proc. Natl. Acad.Sci. U. S. A. 98 .2001; 1853–1858.
65. E. Mammadova-Bach, P. Zigrino, C. Brucker, C. Bourdon,
M. Freund, A. De Arcangelis, S.I. Abrams, G. Orend, C.
Gachet, P.H. Mangin, Platelet integrin α6 β1controls lung
metastasis through direct binding to cancer cell-derived
ADAM9, JCI Insight 1.2016; e88245.
66.Y.J. Kim, L. Borsig, N.M. Varki, A. Varki, P-selectin
deficiency attenuates tumor growth and metastasis, Proc.
Natl. Acad. Sci. 95 .1998; 9325–9330.
67.C. Qi, B. Wei, W. Zhou, Y. Yang, B. Li, S. Guo, J. Li, J.
Ye, J. Li, Q. Zhang, T. Lan,X. He, L. Cao, J. Zhou, J. Geng,
L. Wang, C. Qi, B. Wei, W. Zhou, Y. Yang, B. Li,S. Guo, J.
Li, J. Ye, J. Li, Q. Zhang, T. Lan, X. He, L. Cao, J. Zhou,
J. Geng, L. Wang, P-selectin-mediated platelet adhesion
promotes tumor growth, Oncotarget 6 .2015; 6584–6596.
of adhesive proteins in platelet tumor interaction in vitro
and metastasis formation in vivo, J. Clin. Invest.81. 1988
; 1012–1019,
2.O. Engebraaten, M. Trikha, S. Juell, S. Garman-Vik,
Ø. Fodstad, Inhibition of in vivo tumour growth by
the blocking of host alpha(v)beta3 and alphaII(b)beta3
integrins, Anticancer Res. 29. 2009; 131–137.
3.M.R. Weber, M. Zuka, M. Lorger, M. Tschan, B.E. Torbett, A.
Zijlstra, J.P. Quigley,K. Staflin, B.P. Eliceiri, J.S. Krueger,
P. Marchese, Z.M. Ruggeri, B.H. Felding,Activated tumor
cell integrin αvβ3 cooperates with platelets to promote
extravasation and metastasis from the blood stream,
Thromb. Res. 140 (Suppl.)2016 ; S27–36.
4.B. Felding-Habermann, T.E. O’Toole, J.W. Smith, E.
Fransvea, Z.M. Ruggeri,M.H. Ginsberg, P.E. Hughes, N.
Pampori, S.J. Shattil, A. Saven, B.M. Mueller,Integrin
activation controls metastasis in human breast cancer,
Proc. Natl. Acad.Sci. U. S. A. 98 .2001;1853–1858.
5.S. Mezouar, R. Darbousset, F. Dignat-George, L. Panicot-
Dubois, C. Dubois,Inhibition of platelet activation prevents
the P-selectin and integrin-dependent accumulation of
cancer cell microparticles and reduces tumor growth and
metastasis in vivo, Int. J. Cancer 136. 2015; 462–475.
6.S. Gebremeskel, T. LeVatte, R.S. Liwski, B. Johnston, M.
Bezuhly, The reversible P2Y12 inhibitor ticagrelor inhibits
metastasis and improves survival in mouse models of
cancer, Int. J. Cancer 136 .2015; 234–240.
7.N. Fujita, S. Takagi, The impact of Aggrus/podoplanin on
platelet aggregation and tumour metastasis, J. Biochem.
(Tokyo) 152. 2012 407–413.
8.Y. Kato, M. Kaneko, M. Sata, N. Fujita, T. Tsuruo, M.
Osawa, Enhanced expression of Aggrus (T1alpha/
Podoplanin), a platelet-aggregation-inducing factor in lung
squamous cell carcinoma, Tumor Biol. 26 .2005 ; 195–200.
9.S. Takagi, T. Oh-hara, S. Sato, B. Gong, M. Takami, N.
Fujita, Expression of Aggrus/podoplanin in bladder
cancer and its role in pulmonary metastasis, Int. J.Cancer
134.2014; 2605–2614.
10.Y. Kato, N. Fujita, A. Kunita, S. Sato, M. Kaneko, M.
Osawa, T. Tsuruo, Molecular identification of Aggrus/
T1alpha as a platelet aggregation-inducing factor
expressed in colorectal tumors, J. Biol. Chem. 278. 2003;
51599–51605.
11.C.L. Chaffer, R.A. Weinberg, A perspective on cancer cell
metastasis, Science 331.2011; 1559–1564
12.H. Läubli, L. Borsig, Selectins as mediators of lung
metastasis, Cancer Microenviron. 3 .2010 ; 97–105.
13.Y. Liu, P. Jiang, K. Capkova, D. Xue, L. Ye, S.C. Sinha,
N. Mackman, K.D. Janda, C. Liu, Tissue factor-activated
coagulation cascade in the tumor microenvironment is
critical for tumor progression and an effective target for
therapy, Cancer Res. 71. 2011 ; 6492–6502,
14.W. Ruf, N. Yokota, F. Schaffner, Tissue factor in cancer
progression and angio- genesis, Thromb. Res. 125 .2010;
S36–S38.
15.H.-M. Ko, H.H. Jung, K.H. Seo, Y.-R. Kang, H.-A. Kim,
S.J. Park, H.-K. Lee, S.-Y. Im, Platelet-activating factor-
induced NF-kappaB activation enhances VEGF expres-
sion through a decrease in p53 activity, FEBS Lett. 580
(2006) 3006–3012.
16.L. Sun, Z. He, J. Ke, S. Li, X. Wu, L. Lian, X. He, X.
He, J. Hu, Y. Zou, X. Wu, P. Lan, PAF receptor antagonist
Ginkgolide B inhibits tumourigenesis and angiogenesis
in colitis-associated cancer, Int. J. Clin. Exp. Pathol. 8
.2015; 432–440.
17. B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-
Pleszczynski,G. Montrucchio, G. Camussi, PAF produced
by human breast cancer cells promotes migration and
proliferation of tumor cells and neo-angiogenesis, Am. J.
Pathol.157 .2000; 1713–1725.
18.M. Labelle, S. Begum, R.O. Hynes, Direct signaling
between platelets and cancer cells induces an epithelial-
mesenchymal-like transition and promotes metastasis,
Cancer Cell 20 .2011; 576–590.
19.Y. Wang, H. Zhang, Platelet-induced inhibition of tumor
cell growth, Thromb. Res. 123 .2008; 324–330.
20.J.V. Michael, J.G.T. Wurtzel, G.F. Mao, A.K. Rao, M.A.
Kolpakov, A. Sabri,N.E. Hoffman, S. Rajan, D. Tomar, M.
Madesh, M.T. Nieman, J. Yu, L.C. Edelstein, J.W. Rowley,
A.S. Weyrich, L.E. Goldfinger, Platelet microparticles
infiltrating solid tumors transfer miRNAs that suppress
tumor growth, Blood 130 .2017; 567–580.
21. J.F. Di Stefano, M. Kirchner, K. Dagenhardt, N. Hagag,
Activation of cancer cell proteases and cytotoxicity by
EGF and PDGF growth factors, Am J Med Sci 300 .1990;
9–15.
22.J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer:
biological implications and therapeutic opportunities, Nat.
Rev. Cancer 10 .2010; 9–22.
23.T.E. Maione, G.S. Gray, J. Petro, A.J. Hunt, A.L.
Donner, S.I. Bauer, H.F. Carson, R.J. Sharpe, Inhibition of
angiogenesis by recombinant human platelet factor-4 and
related peptides, Science 247 .1990; 77–79.
24.S. Struyf, M.D. Burdick, P. Proost, J.V. Damme, R.M.
Strieter, Platelets release CXCL4L1, a nonallelic variant
of the chemokine platelet Factor-4/CXCL4 and potent
inhibitor of angiogenesis, Circ. Res. 95 .2004; 855–857.
25.S. Struyf, M.D. Burdick, E. Peeters, K.V. den Broeck,
C. Dillen, P. Proost,J.V. Damme, R.M. Strieter, Platelet
Factor-4 variant chemokine CXCL4L1 inhibits melanoma
and lung carcinoma growth and metastasis by preventing
angiogenesis, Cancer Res. 67.2007; 5940–5948.
26.J. Vandercappellen, S. Liekens, A. Bronckaers, S. Noppen,
I. Ronsse, C. Dillen, M. Belleri, S. Mitola, P. Proost, M.
Presta, S. Struyf, J. Van Damme, The COOH- terminal
peptide of platelet factor-4 variant (CXCL4L1/PF-
4var47-70) strongly inhibits angiogenesis and suppresses
B16 melanoma growth in vivo, Mol. Cancer Res. 8(2010) 322–334.
27.P. Allavena, A. Sica, C. Garlanda, A. Mantovani, The
yin-Yang of tumor-associated macrophages in neoplastic
progression and immune surveillance, Immunol. Rev.
222 (2008) 155–161.
28.G.T. Lee, J.H. Hong, C. Kwak, J. Woo, V. Liu, C.
Lee, I.Y. Kim, Effect of dominant negative transforming
growth factor-beta receptor type II on cytotoxic activity of
RAW 264.7, a murine macrophage cell line, Cancer Res.
67 (2007) 6717–6724.
29.L. Shen, J.M. Smith, Z. Shen, M. Eriksson, C.
Sentman, C.R. Wira, Inhibition of human neutrophil
degranulation by transforming growth factor-β1, Clin.
Exp. Immunol. 149 (2007) 155–161.
30.M. Labelle, S. Begum, R.O. Hynes, Platelets guide the
formation of early metastatic niches, Proc. Natl. Acad.
Sci. U. S. A. 111 (2014) E3053–3061.
31.S. Mezouar, D. Mege, R. Darbousset, D. Farge, P.
Debourdeau, F. Dignat-George, L. Panicot-Dubois, C.
Dubois, Involvement of platelet-derived microparticles
in tumor progression and thrombosis, Semin. Oncol.
41 (2014) 346–358.
32.C. Yang, R. Ma, T. Jiang, M. Cao, L. Zhao, Y. Bi, J.
Kou, J. Shi, X. Zou, Contributions of phosphatidylserine-
positive platelets and leukocytes and micro- particles to
hypercoagulable state in gastric cancer patients, Tumor
Biol. 37 (2016) 7881–7891.
33.A. Rank, S. Liebhardt, J. Zwirner, A. Burges, R.
Nieuwland, B. Toth, Circulating microparticles in patients
with benign and malignant ovarian tumors, Anticancer
Res. 32 (2012) 2009–2014.
34.J.G. Ren, Q.W. Man, W. Zhang, C. Li, X.P. Xiong, J.Y.
Zhu, W.M. Wang, Z.J. Sun, J. Jia, W.F. Zhang, Y.F. Zhao, G.
Chen, B. Liu, Elevated level of circulating platelet- derived
microparticles in oral cancer, J. Dent. Res. 95 (2016) 87–
93.
35.C.-C. Tseng, C.-C. Wang, H.-C. Chang, T.-H. Tsai, L.-T.
Chang, K.-T. Huang, S. Leu, C.-H. Yen, S.-F. Liu, C.-H.
Chen, C.-T. Yang, H.-K. Yip, M.-C. Lin, Levels of circu-
lating microparticles in lung cancer patients and possible
prognostic value, Dis. Markers 35 (2013) 301–310.
36.L. Zhao, Y. Bi, J. Kou, J. Shi, D. Piao, Phosphatidylserine
exposing-platelets and microparticles promote
procoagulant activity in colon cancer patients, J. Exp. Clin.
Cancer Res. 35 (2016).
37.B. Toth, S. Liebhardt, K. Steinig, N. Ditsch, A. Rank,
I. Bauerfeind, M. Spannagl, K. Friese, A.J. Reininger,
Platelet-derived microparticles and coagulation activa-
tion in breast cancer patients, Thromb. Haemost. 100
(2008) 663–669.
38.K. Haubold, M. Rink, B. Spath, M. Friedrich, F.K.-H.
Chun, G. Marx, A. Amirkhosravi, J.L. Francis, C.
Bokemeyer, B. Eifrig, F. Langer, Tissue factor procoagulant
activity of plasma microparticles is increased in patients
with early- stage prostate cancer, Thromb. Haemost. 101
(2009) 1147–1155.
39.F. van Doormaal, A. Kleinjan, R.J. Berckmans, N.
Mackman, D. Manly,P.W. Kamphuisen, D.J. Richel, H.R.
Büller, A. Sturk, R. Nieuwland, Coagulation activation
and microparticle-associated coagulant activity in cancer
patients, Thromb. Haemost. 108 (2012) 160–165..
40.E. Campello, L. Spiezia, C.M. Radu, C. Bulato, M.
Castelli, S. Gavasso, P. Simioni, Endothelial, platelet,
and tissue factor-bearing microparticles in cancer patients
with and without venous thromboembolism, Thromb.
Res. 127 (2011) 473–477.
41.O.P. Barry, D. Pratico, J.A. Lawson, G.A. FitzGerald,
Transcellular activation of platelets and endothelial cells
by bioactive lipids in platelet microparticles, J. Clin.
Invest. 99 (1997) 2118–2127.
42.S. Miyamoto, M.A. Kowalska, C. Marcinkiewicz,
M.M. Marcinkiewicz, D. Mosser, L.H. Edmunds, S.
Niewiarowski, Interaction of leukocytes with platelet
micro- particles derived from outdated platelet
concentrates, Thromb. Haemost. 80 (1998) 982–988.
43.M. Baj-Krzyworzeka, M. Majka, D. Pratico, J. Ratajczak,
G. Vilaire, J. Kijowski, R. Reca, A. Janowska-Wieczorek,
M.Z. Ratajczak, Platelet-derived microparticles stimulate
proliferation, survival, adhesion, and chemotaxis of
hematopoietic cells, Exp. Hematol. 30 (2002) 450–459.
44.H.K. Kim, K.S. Song, J.-H. Chung, K.R. Lee, S.-N. Lee,
Platelet microparticles in- duce angiogenesis in vitro, Br. J.
Haematol. 124 (2004) 376–384.
45.A. Janowska-Wieczorek, M. Wysoczynski, J. Kijowski,
L. Marquez-Curtis,B. Machalinski, J. Ratajczak, M.Z.
Ratajczak, Microvesicles derived from activated platelets
induce metastasis and angiogenesis in lung cancer, Int.
J. Cancer 113 (2005) 752–760.
46.A. Janowska-Wieczorek, L.A. Marquez-Curtis, M.
Wysoczynski, M.Z. Ratajczak,Enhancing effect of platelet-
derived microvesicles on the invasive potential of breast
cancer cells, Transfusion (Paris) 46 (2006) 1199–1209.
47.O. Dashevsky, D. Varon, A. Brill, Platelet-derived
microparticles promote inva- siveness of prostate cancer
cells via upregulation of MMP-2 production, Int. J.
Cancer 124 (2009) 1773–1777.
48.H. Liang, X. Yan, Y. Pan, Y. Wang, N. Wang, L. Li, Y.Liu, X. Chen, C.-Y. Zhang, H. Gu, K. Zen, MicroRNA-223
delivered by platelet-derived microvesicles pro- motes
lung cancer cell invasion via targeting tumor suppressor
EPB41L3, Mol. Cancer 14 .2015; 58.
49.A. Laios, S. O’Toole, R. Flavin, C. Martin, L. Kelly,
M. Ring, S.P. Finn, C. Barrett, M. Loda, N. Gleeson, T.
D’Arcy, E. McGuinness, O. Sheils, B. Sheppard, J.O’.
Leary, Potential role of miR-9 and miR-223 in recurrent
ovarian cancer, Mol. Cancer 7 .2008 ; 35.
50. D.L. Sprague, B.D. Elzey, S.A. Crist, T.J. Waldschmidt,
R.J. Jensen, T.L. Ratliff, Platelet-mediated modulation
of adaptive immunity: unique delivery of CD154 signal
by platelet-derived membrane vesicles, Blood 111 .2008;
5028–5036.
51. Y. Liu, P. Jiang, K. Capkova, D. Xue, L. Ye, S.C. Sinha,
N. Mackman, K.D. Janda,C. Liu, Tissue factor-activated
coagulation cascade in the tumor microenvironment is
critical for tumor progression and an effective target for ;
52.W. Ruf, N. Yokota, F. Schaffner, Tissue factor in cancer
progression and angiogenesis,Thromb. Res. 125 .2010;
S36–S38.
53.H.-M. Ko, H.H. Jung, K.H. Seo, Y.-R. Kang, H.-A.
Kim, S.J. Park, H.-K. Lee, S.-Y. Im,Platelet-activating
factor-induced NF-kappaB activation enhances VEGF
expressionthrough a decrease in p53 activity, FEBS Lett.
580 .2006 ; 3006–3012.
54.L. Sun, Z. He, J. Ke, S. Li, X. Wu, L. Lian, X. He, X.
He, J. Hu, Y. Zou, X. Wu, P. Lan,PAF receptor antagonist
Ginkgolide B inhibits tumourigenesis and angiogenesis in
colitis-associated cancer, Int. J. Clin. Exp. Pathol. 8.2015;
432–440.
55. B. Bussolati, L. Biancone, P. Cassoni, S. Russo, M. Rola-
Pleszczynski,G. Montrucchio, G. Camussi, PAF produced
by human breast cancer cells promotes migration and
proliferation of tumor cells and neo-angiogenesis, Am. J.
Pathol. 157 .2000 ; 1713–1725.
56.F. Bussolino, M. Arese, G. Montrucchio, L. Barra, L.
Primo, R. Benelli, F. Sanavio,M. Aglietta, D. Ghigo, M.R.
Rola-Pleszczynski, Platelet activating factor produced in
vitro by Kaposi’s sarcoma cells induces and sustains in
vivo angiogenesis, J.Clin. Invest. 96 .1995 ; 940–952.
57.E.G. Robert, J.D. Hunt, Lipid messengers as targets for
antiangiogenic therapy,Curr. Pharm. Des. 7 .2001 ; 1615–
1626.
58.J.S. Palumbo, K.E. Talmage, J.V. Massari, C.M.L.
Jeunesse, M.J. Flick,K.W. Kombrinck, M. Jirousková,
J.L. Degen, Platelets and fibrin(ogen) increase metastatic
potential by impeding natural killer cell-mediated
elimination of tumor cells, Blood 105 .2005; 178–185.
59.H.-G. Kopp, T. Placke, H.R. Salih, Platelet-derived
transforming growth factor-beta down-regulates
NKG2D thereby inhibiting natural killer cell antitumor
reactivity,Cancer Res. 69.2009; 7775–7783.
60.K. Egan, N. Cooke, D. Kenny, Living in shear: platelets
protect cancer cells from shear induced damage, Clin. Exp.
Metastasis 31 .2014; 697–704.
61.S. Karpatkin, E. Pearlstein, C. Ambrogio, B.S. Coller,
Role of adhesive proteins in platelet tumor interaction in
vitro and metastasis formation in vivo, J. Clin. Invest. 81
1988; 1012–1019.
62.O. Engebraaten, M. Trikha, S. Juell, S. Garman-Vik,.
Fodstad, Inhibition of in vivo tumour growth by the
blocking of host alpha(v)beta3 and alphaII(b)beta3
integrins, Anticancer Res. 29. 2009; 131–137.
63.M.R. Weber, M. Zuka, M. Lorger, M. Tschan, B.E.
Torbett, A. Zijlstra, J.P. Quigley,K. Staflin, B.P.
Eliceiri, J.S. Krueger, P. Marchese, Z.M. Ruggeri, B.H.
Felding,Activated tumor cell integrin αv β3 cooperates
with platelets to promote extravasation and metastasis
from the blood stream, Thromb. Res. 140 (Suppl. 1) .2016
; S27–36.
64.B. Felding-Habermann, T.E. O’Toole, J.W. Smith, E.
Fransvea, Z.M. Ruggeri,M.H. Ginsberg, P.E. Hughes, N.
Pampori, S.J. Shattil, A. Saven, B.M. Mueller,Integrin
activation controls metastasis in human breast cancer,
Proc. Natl. Acad.Sci. U. S. A. 98 .2001; 1853–1858.
65. E. Mammadova-Bach, P. Zigrino, C. Brucker, C. Bourdon,
M. Freund, A. De Arcangelis, S.I. Abrams, G. Orend, C.
Gachet, P.H. Mangin, Platelet integrin α6 β1controls lung
metastasis through direct binding to cancer cell-derived
ADAM9, JCI Insight 1.2016; e88245.
66.Y.J. Kim, L. Borsig, N.M. Varki, A. Varki, P-selectin
deficiency attenuates tumor growth and metastasis, Proc.
Natl. Acad. Sci. 95 .1998; 9325–9330.
67.C. Qi, B. Wei, W. Zhou, Y. Yang, B. Li, S. Guo, J. Li, J.
Ye, J. Li, Q. Zhang, T. Lan,X. He, L. Cao, J. Zhou, J. Geng,
L. Wang, C. Qi, B. Wei, W. Zhou, Y. Yang, B. Li,S. Guo, J.
Li, J. Ye, J. Li, Q. Zhang, T. Lan, X. He, L. Cao, J. Zhou,
J. Geng, L. Wang, P-selectin-mediated platelet adhesion
promotes tumor growth, Oncotarget 6 .2015; 6584–6596.
)